ReferenceID 578
Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib
Oncogene
Activating BRAF mutations promote constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway and are common in a variety of human malignancies, including melanoma and colon cancer. Several s
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 578
- Evidence Id
- 17168
- Core Evidence Id
- 17168
- Source Reference Id
- 1149
- Herb2 Reference Id
- HBREF001936
- Subject Paper Key
- HBIN042379_27321184
- Pubmed Id
- 27321184
- Doi
- 10.1038/onc.2016.214
- Paper Title
- Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib
- Paper Abstract
- Activating BRAF mutations promote constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway and are common in a variety of human malignancies, including melanoma and colon cancer. Several small molecule BRAF inhibitors such as vemurafenib have been developed and demonstrate remarkable clinical efficacy. However, resistance typically emerges in most melanoma patients. Studies have demonstrated that reactivation of MAPK signaling via CRAF overexpression and dysregulation is a mechanism for vemurafenib resistance in melanoma. Prohibitins (PHBs) are highly conserved proteins that are thought to control the cell cycle, senescence and tumor suppression. PHB1 is essential for CRAF-mediated ERK1/2 activation through direct binding to CRAF. We developed a CRAF-mediated model of vemurafenib resistance in melanoma cells to assess the importance of the interaction between CRAF and PHB1 in resistance to BRAF-targeting agents. We demonstrate that CRAF overexpression renders melanoma cells resistant to BRAF-targeting agents. Moreover, treatment with the natural compound rocaglamide A disrupts the interaction between PHB and CRAF in melanoma cells, thus reducing MEK1/2 and ERK1/2 signaling, inhibiting melanoma cell growth and inducing apoptosis. The efficacy of these compounds was also demonstrated in a human melanoma xenograft model. Taken together, these data suggest that PHB1 may serve as a novel, druggable target in CRAF-mediated vemurafenib resistance.
- Journal
- Oncogene
- Publish Year
- 2017
- Experiment Subject
- melanoma patients
- Experiment Type
- Clinical Experiment
- Phenotype Related
- Paper Title Cn
- Paper Title En
- Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib
- Bilingual Status
- semi_complete